SCHEMBL24399600

SCHEMBL24399600

Cc1ccc2c(Nc3ccc(F)c(Cl)c3)nccc2c1N

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 1/20 0.54
CSF1R P07333 1/20 0.54
BRAF P15056 1/20 0.54
DDR1 Q08345 1/20 0.54
DDR2 Q16832 1/20 0.54
EGFR P00533 8/20 0.52
TDO2 P48775 6/20 0.50
GRM1 Q13255 1/20 0.50
KDR P35968 4/20 0.46
FBP1 P09467 2/20 0.46
AURKA O14965 1/20 0.46
ERBB2 P04626 1/20 0.46
INSR P06213 1/20 0.46
PDGFRB P09619 1/20 0.46
FLT4 P35916 1/20 0.46
CLK1 P49759 1/20 0.46
EPHB4 P54760 1/20 0.46
TEK Q02763 1/20 0.46
AURKB Q96GD4 1/20 0.46
RAPGEF4 Q8WZA2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3776216 0.84 BRAF (0.54) RAF1CSF1RBRAFDDR1DDR2
SCHEMBL31406748 0.84 BRAF (0.54) RAF1CSF1RBRAFDDR1DDR2
SCHEMBL26373434 0.83 PIP4K2A (0.50)
SCHEMBL24399634 0.82 FADS1 (0.54) RAF1CSF1RBRAFDDR1DDR2
SCHEMBL24268077 0.82 RAPGEF4 (0.49) RAF1CSF1RBRAFDDR1DDR2
SCHEMBL24399614 0.81 ADORA2A (0.46) RAF1CSF1RBRAFDDR1DDR2
SCHEMBL23015931 0.81 RAF1 (0.49) RAF1CSF1RBRAFDDR1DDR2
SCHEMBL26207944 0.81 KDR (0.46) RAF1CSF1RBRAFDDR1DDR2
SCHEMBL26066666 0.80 TDO2 (0.54) EGFRTDO2GRM1KDRFBP1
SCHEMBL30559484 0.79 BRAF (0.57) RAF1CSF1RBRAFDDR1DDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2023-10-05 US disclosed
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2023-10-05 US disclosed
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2023-10-05 US disclosed
EP-4238967-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2023-09-06 EP disclosed
EP-4238967-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2023-09-06 EP disclosed
WO-2022089219-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2022-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF AHR, ARNT, NOTUM RAF1 2075/4885CSF1R 987/4885BRAF 720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.